Malignant pleural mesothelioma

This early-stage trial is testing whether a new type of CAR-T cell therapy is safe for people with malignant pleural mesothelioma, a rare and aggressive cancer of the lung lining. The CAR-T cells are engineered to target a protein called mesothelin on cancer cells and include a b…

This phase 2 trial tests a combination of three types of drugs—an immunotherapy (pembrolizumab), a targeted therapy (lenvatinib), and chemotherapy (pemetrexed plus cisplatin or carboplatin)—as a first treatment for people with advanced malignant pleural mesothelioma that cannot b…

This phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …

This early study tests whether giving nivolumab (an immunotherapy) along with standard chemotherapy before surgery is safe and feasible for people with malignant pleural mesothelioma. The main goal is to see if this approach delays surgery by more than 30 days. 22 participants wi…

This study tests whether adding the drug cediranib to standard chemotherapy (cisplatin and pemetrexed) can help people with malignant pleural mesothelioma, a rare and aggressive lung cancer. In the first phase, researchers found the safest dose of cediranib. In the second phase, …

This study tests a new radiation technique called IMRT for people with malignant pleural mesothelioma, a rare lung cancer. The goal is to see if combining surgery, chemotherapy, and this targeted radiation is safe and reduces severe lung side effects. About 65 adults with early-s…

This early-phase trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy (cisplatin and pemetrexed) before and after surgery can help people with resectable pleural mesothelioma. The study includes 28 participants with stage I-III disease. The…

This study tests a new treatment using specially engineered immune cells (called CAR-NK cells) from donated cord blood, given alongside chemotherapy, for people with advanced kidney cancer, mesothelioma, or bone cancer. The goal is to find a safe dose and see if it helps control …

This study tests a new drug called TRC102 (methoxyamine) combined with standard chemotherapy (cisplatin and pemetrexed) in people with advanced solid tumors or mesothelioma that has not responded to prior treatment. The goal is to see if TRC102 can make cancer cells more sensitiv…

This early-phase trial tests an experimental drug called BAY 1895344 combined with standard chemotherapy (cisplatin, with or without gemcitabine) in people with advanced solid tumors, especially urothelial cancer. The goal is to find the best dose and see how safe the combination…

This study tests a new drug called volrustomig combined with chemotherapy against standard treatments for people with advanced pleural mesothelioma that cannot be removed by surgery. About 861 adults with this rare lung cancer will be randomly assigned to receive either the exper…

This phase 2b trial tests whether the immunotherapy drug tremelimumab can help people with advanced mesothelioma live longer. About 571 patients who have already tried standard chemotherapy will receive either tremelimumab or a placebo. The main goal is to see if the drug improve…

This study tests a treatment using a patient's own immune cells (T cells) that are genetically modified to recognize and attack a protein called mesothelin found on cancer cells. The treatment is given through a tube in the chest to people with malignant pleural disease, includin…

This study tests whether giving immunotherapy drugs (nivolumab with or without ipilimumab) before surgery is safe and feasible for people with resectable malignant pleural mesothelioma. About 30 adults with epithelial or biphasic mesothelioma will receive the drugs, then undergo …

This study tests whether adding a targeted drug (anetumab ravtansine) to an immunotherapy (pembrolizumab) works better than the immunotherapy alone for people with a specific type of mesothelioma. The targeted drug delivers chemotherapy directly to cancer cells that have a certai…

This early-phase trial is testing whether combining the immunotherapy drug pembrolizumab with a precise type of radiation (IMPRINT) is safe for people with malignant pleural mesothelioma, a rare cancer of the lung lining. The study involves 7 participants whose cancer cannot be r…

This study is testing a new approach for people with malignant pleural mesothelioma, a rare lung cancer. It combines high-dose radiation (including a special boost to target bulky tumors) with surgery to remove the affected tissue. The main goal is to find the highest safe radiat…

This study tests a new way to give radiation therapy to people with malignant pleural mesothelioma, a rare and serious lung cancer. The treatment uses a special machine called Tomotherapy to deliver high doses of radiation over just 5 days. The goal is to see if this short, inten…

This study is looking at whether changes in a blood test called tumor fraction can help predict how well immunotherapy works in people with non-small cell lung cancer or kidney cancer. About 100 adults will have blood samples taken before and during their standard treatment. The …